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Myotonic dystrophy type 1 (DM1) is an RNA-mediated disorder caused by a non-coding CTG repeat expansion
that, in particular, provokes functional alteration of CUG-binding proteins. As a consequence, several genes
with misregulated alternative splicing have been linked to clinical symptoms. In our search for additional mo-
lecular mechanisms that would trigger functional defects in DM1, we took advantage of mutant gene-carrying
human embryonic stem cell lines to identify differentially expressed genes. Among the different genes found
to be misregulated by DM1 mutation, one strongly downregulated gene encodes a transcription factor,
ZNF37A. In this paper, we show that this defect in expression, which derives from a loss of RNA stability, is con-
trolled by the RNA-binding protein, CUGBP1, and is associated with impairedmyogenesis—a functional defect
reminiscent of that observed inDM1. Lossof theZNF37Aprotein results in changes in theexpressionof the sub-
unita1 of the receptor for the interleukin 13. This suggests that the pathological molecular mechanisms linking
ZNF37A and myogenesis may involve the signaling pathway that is known to promote myoblast recruitment
during development and regeneration.
INTRODUCTION
Myotonic dystrophy type 1 (DM1), the most common form of
adult-onset muscular dystrophy, is caused by an abnormal
CTG repeat expansion in the 3′ UTR (untranslated region) of
the gene encoding a protein kinase (DMPK). This disease has
apeculiarmolecular basis becausemost of the clinical symptoms
are not directly due to a defect in the function of the mutant
DMPK gene (1,2). Instead, abnormalities are introduced in the
processing of a variety of genes by an indirectly triggered defect-
ive activity of proteins involved inmRNA processing; this is the
result of the presence of the mutant DMPK RNA in the cell
nucleus (3). The identification of RNA-binding proteins bound
to the abnormal CUG repeat expansion indicated an RNA
gain-of-function model for DM1. Indeed, a number of changes
in tissue-specific patterns of gene alternative splicing have
been shown to contribute to the specific symptoms in DM1
patients (3,4).
In addition to these mechanisms, or as a secondary conse-
quence of abnormal splicing in a signaling cascade, more
recent studies have highlighted the existence of gene expression
alterations in DM1 cells. Using differential transcriptomics, we
specifically identified 15 genes that exhibited up- or downregu-
lation in cells differentiated from stem cell lines derived from
humanembryos characterized as carrying theDM1gene in apre-
implantation genetic diagnosis (PGD) procedure (5,6). How
∗To whom correspondence should be addressed. Email: cmartinat@istem.genethon.fr
# The Author 2013. Published by Oxford University Press. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
Human Molecular Genetics, 2013, Vol. 22, No. 25 5188–5198
doi:10.1093/hmg/ddt373
Advance Access published on August 6, 2013
such changes in gene expression may contribute to the disease
phenotype remains to be established. Within this framework,
ZNF37A—one of the most severely downregulated genes—
particularly attracted our attention because it is a potential tran-
scription factor.Modificationof expressionof transcription factors
has been described in DM1 and may provide a powerful explan-
ation for broad gene expression changes. This has been demon-
strated for the abnormal heart Nkx2.5 induction in a DM1 mouse
model (7,8). These findings also highlight the notion that the re-
quirement for transcription factors in different tissues expressing
the mutation may account for the multisystemic nature of DM1.
In the general framework of our search for new pathological
mechanisms of DM1, we began with the identification of the ex-
pression defect of ZNF37A and subsequently explored its role
in the DM1 pathophysiology. Derivatives of human ES cell
lines were used in this study because they provide the dual advan-
tage of the production of an unlimited number of cells, as a result
of their indefinite capacity for self-renewal, and their ability to
differentiate into homogenous cell populations of discrete
phenotypes (9). As a complement to such studies, PGD permits
the precise characterization of the genomic defect of the cell lines.
Our study reveals that the altered expression of the Krab-
domain, zinc-finger transcriptional repressor factor ZNF37A
bears functional consequences in myogenesis. The myogenic
function of ZNF37A may be related to its transcriptional effect
on IL13RA1—the expression of which was also altered in our
original transcriptomic analysis (5)—because it is a subunit for
the receptor to the myoblast recruitment factor interleukin 13
(IL13).
RESULTS
ZNF37A expression is specifically altered in cells
with DM1 mutation
In our original transcriptomic analysis of cells differentiated
from stem cell lines derived from embryos carrying a DM1
gene (data available at GEO Data Bank; accession number
GSE7214, http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?a
cc=GSE7214), ZNF37A was found highly downregulated in
human embryonic stem cells (hESCs), hESCs-derived mesen-
chymal stem cells (MSCs) and hESCs-derived neural stem
cells (NSCs) (5). As previously shown, hES-derived MSCs are
characterized by expression, at near homogeneity, of CD29
(b1-integrin), CD44 (H-CAM), CD73, CD105 and CD166,
and are able to differentiate along osteogenic and adipogenic
lineages when grown in appropriate conditions (10). The two
DM1 hESCs, VUB03_DM and VUB24_DM, carry 1000
and 3000 CTG triplet repeats, respectively, and their differenti-
ation into NSCs and MSCs does not affect the size of the CTG
triplet repeats (5). ZNF37A gene encodes a zinc-finger protein
that exhibits all the characteristics of the Krab-containing zinc-
finger protein family. This gene belongs to a cluster of genes
encoding members of that family, which is located in the
pericentromeric region of the chromosome 10p11.2-10q11.2
(Fig. 1A). Specific down expression of ZNF37A was confirmed
by quantitative reverse transcription-PCR (Fig. 1B; Supplemen-
taryMaterial, Fig. S1) and in situ hybridization (Supplementary
Material, Fig. S1B). At the protein level, western blot and im-
munofluorescence analysis (Fig. 1D–F) also showed that
ZNF37A expression was decreased in DM1 hES-derived
MSCs, whereas the protein could be easily detected in the
nucleus of control wild-type cells. Similarly, a strong gene ex-
pression defect was also observed both in skeletal muscle cell
and brain tissue samples from DM1 patients (Fig. 1G–F).
DM1 affects ZNF37A expression by means of CUGBP1
control of its mRNA stability
Molecular mechanisms linking this defect with DM1 were
explored by analyzing the hypothesis that the stability of
ZNF37A mRNA was compromised in diseased cells. Indeed,
measurement of the stability of transcripts following inhibition
of the transcription with Actinomycin D indicated a specific in-
stability of ZNF37AmRNA inDM1hES-derivedMSCs as com-
pared to control cells, whereas no effect of the treatment was
observed on ZNF33A and ZNF37B, two other genes of the
same family that belong to the same chromosomal cluster
(Figs 1A and 2A; Supplementary Material, Fig. S2A).
A part of the 5′ UTR region of the ZNF37A mRNA contains
several UG-rich motifs (Fig. 2B); similar motifs have been
shown to be CUGBP1-binding sites (11). This observation, to-
gether with the fact that CUGBP1 function is known to be aber-
rant in DM1, suggested a link between CUGBP1 and the
ZNF37AmRNA instability. To test this hypothesis, a luciferase
reporter plasmid was used in which this part of the
5′UTR_ZNF37A had been cloned upstream of the luciferase
gene under a CMV promoter (Fig. 2B). Transient transfection
of this construct in DM1 hES-derived MSCs resulted in a statis-
tically significant decrease in luciferase expression as compared
with control cells, whereas no difference was observed in trans-
fection efficiency (Fig. 2C; Supplementary Material, Fig. S2B).
Similar results were obtained in wild-type HEK 293 cells after
co-transfection of the luciferase construct together with a
plasmid expressing a DMPK minigene that contains an abnor-
mally long stretch of 960 interrupted CUG repeats (Fig. 2F; Sup-
plementary Material, Fig. S2C and D) (12). The overexpression
of CUGBP1 resulted in a similar reduction in luciferase expres-
sion, whereas the overexpression of MBNL1, another RNA-
binding protein known to be affected in DM1, had no effect
(Fig. 2F). Whether CUGBP1 controlled the expression of
ZNF37A by means of direct binding to RNA was determined
using gel shift retardation assays. Thus, four different RNA frag-
ments derived from theZNF37A5′UTRwere incubatedwith in-
creasing amounts of recombinant CUGBP1 protein and the
complexes were separated on a native polyacrylamide gel.
CUGBP1 seemed tobindpredominantly twodifferent fragments
(fragment 2 and fragment 4) of the 5′ UTR of ZNF37A (Fig. 2D
andE).The deletionof a region that containedCUGBP1-binding
motifs in 5′UTR_ZNF37A-luc construct (Delta A) resulted in a
loss of effect of the DMPK minigene containing 960 CUG
repeats aswell as a loss of effect of CUGBP1. In contrast, the de-
letion of a region (Delta B) that does not contain putative
CUGBP1-binding motifs did not affect the response of the
5′UTR_ZNF37A-luc construct (Fig. 2F). However, we cannot
exclude, as it was recently suggested by different studies, that
the RNA secondary structure may facilitate CUGBP1 binding
by bringing into close proximity UGU sequences dispersed
throughout the region (13,14). Thus, the identification of
CUGBP1-binding sites might not be clearly as simple as
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Figure1.ZNF37A is a transcription factor specifically downregulated inDM1hESC, its progenyandpatientsbiopsies. (A)ZNF37Abelongs to a gene cluster localized
on thepericentromeric part of the chromosome10. (B)Quantitative real-timeRT–PCRanalysis ofZNF37A,ZNF37B,ZNF33AandZNF25expression in the twoDM1
hES cell lines (VUB03_DMandVUB24_DM) and in their differentiated derivatives (NPC andMSC).Data (n ¼ 3) are presented as values of the control VUB01 and
were analyzedwithANOVAfollowedbyStudent’s t-test.∗P ≤ 0.005. (C) ZNF37Anuclear localization by immunostaining on control hES-derivedMSCs (H9) com-
pared with DM1 hES-derivedMSCs (VUB03_DMandVUB24_DM). Nuclei were stained with Dapi. Bar scale ¼ 20 mm. (D)Western blot analysis of ZNF37A ex-
pression inDM1hES-derivedMSCs (VUB03_DMandVUB24_DM) in comparisonwith thewild-type cell line (H9).H3PANwas used as a nuclear positive fraction
control; actinwasused as a loadingcontrol. (E)QuantificationofZNF37Aprotein level afterwesternblot byusing ImageJ software.Similar resultswereobtainedwith
10, 5, 2.5 and 1.25 mg of proteins loaded.Data (n ¼ 3)were normalizedwithHistineH3 level andwere analyzedwith a t-test ANOVA, ∗P , 0.0001. (F) Quantitative
real-timeRT–PCRanalysisofZNF37Aexpression incerebral tissues fromDM1patients aswell as inprimary skeletalmuscle cells isolated fromDM1patients (results
were normalized with the average of control samples). Data are presented as scatter dot plots (line at mean) and were analyzed with the t-test, ∗P , 0.05.
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Figure 2.ZNF37Amisexpression is due tomRNA instabilitymodulated by CUGBP1. (A) Quantitative real-time RT–PCR of ZNF37A in DM1 (VUB03_DM) hES-
derived MSCs treated with actinomycin D compared with control cells (H9). Data are presented as the mean+SEM (n ¼ 3) and were analyzed with the t-test
ANOVA, ∗∗∗P , 0.001. (B) Schematic representation of 5′UTR_ZNF37A-luc constructs containing the ZNF37A-5′ UTR potential RNA-binding protein motifs
(highlight in gray) between the luciferase gene and under the control of CMV promoter. (C) Luciferase expression of 5′UTR_ZNF37A-luc constructs after
co-transfection with a GFP expressing plasmid in DM1 (VUB03_DM) hES-derivedMSCs, when compared with controls. Normalization was achieved by adjusting
to the number ofGFP positive cells. Data are presented as themean+SEM (n ¼ 3) andwere analyzedwith the t-test (ANOVA), ∗P , 0.05. (D) Schematic design of
300 nt sequences inUGUrich regionofZNF37A5′UTRnamed#1, #2,#3,#4.UGUmotifs arehighlighted ingray.DeletionofmutantDeltaA isunderlined inblueand
mutantDeltaB is underlined inpink. (E)Gel shift assayofCUGBP1binding to the fourdifferent regionsofZNF37A5′UTR. IncreasingquantitiesofCUGBP1protein
were incubated with the different ZNF37A 5′ UTR regions (lane 1: 0 ng; lane 2: 37.5 ng; lane 3: 75 ng; lane 4: 150 ng). (F) Luciferase expression of
5′UTR_ZNF37A-luc, Delta A and Delta B constructs in HEK293 cells, cotransfected with the GFP expressing plasmid and the RNA-binding protein CUGBP1,
MBNL1 and DMPK 3′ UTR containing 960 CUG interrupted repeats (pCTG). Normalization was achieved by adjusting to the number of GFP positive cells.
Data are presented as the mean+SEM (n ¼ 3) and were analyzed with the t-test (ANOVA), ∗∗P , 0.001.
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pinpointing extensive UG-rich regions and further investigation
will be necessary to enable accurate prediction of CUGBP1
targets.
An alternative hypothesis for explaining the defect in
ZNF37A expression was the presence of a putative alternative
splice site in the5′UTRofZNF37A,whichmayalter the stability
of the ZNF37A transcript. To test this hypothesis, the construct
was inserted upstream of the luciferase gene in an inverse pos-
ition. Similar results were obtained regardless of the sense of
the insertion (Supplementary Material, Fig. S2E), thus ruling
out the presence of an alternative splicing defect. This was
further confirmed by the lack of effect of either CUGBP1 over-
expression or the introductionof the construct carrying960CUG
repeats on the alternative splicing of this region (Supplementary
Material, Fig. S2F). Altogether, these results suggest that
DM1-specific ZNF37A down expression is linked to a
CUGBP1-dependent mRNA destabilization mechanism.
ZNF37A down expression results in altered myogenesis
that may involve the IL13 receptor a1 subunit
In an attempt to identify a functional link between the defect in
ZNF37A expression and DM1, the former’s role was explored.
Judging from its nuclear subcellular localization (Fig. 1D–E)
and its sequence analysis, ZNF37A exhibits all the characteristics
ofKrab-containing zinc-finger proteins,which generally function
as transcriptional repressors (15). Accordingly, co-immunopreci-
pitation on the nuclear fraction of control hES-derived MSCs
demonstrated a direct interaction between ZNF37A and Kap1, a
common co-repressor ofKrab-domain transcription factors (Sup-
plementary Material, Fig. S3A).
It was, therefore, postulated that ZNF37A down expression in
DM1 cells might induce upregulation of its target genes in the
same cells. Among the seven candidates found to be upregulated
in our original study (5), the a1 chain of the receptor to IL13
(IL13RA1) was especially appealing because its expression
level was inversely correlated to that of ZNF37A not only in
mutant hES cells and derivatives at all stages and types of differ-
entiation but also in DM1 patients’ myotubes samples (Fig. 3A
and B; Supplementary Material, Fig. S3B). The knockdown of
ZNF37A expression by specific siRNA in wild-type H9 hES-
derived MSCs led to an increased expression of IL13RA1, con-
firming that ZNF37A negatively controls the expression of
IL13RA1 (Fig. 3C). As a control of the specificity of those
effects,ZNF37A-directed siRNAhad no effect on the expression
level of eIF2S3, another gene upregulated in the mutant cells
(Supplementary Material, Fig. S3C). Chromatin immunopreci-
pitation directed against ZNF37A, followed by a quantitative
PCR analysis with primers covering the entire IL13RA1 pro-
moter, revealed a potential-binding site for ZNF37A that did
not exist in the promoter region of eIF2S3 (Fig. 3D; Supplemen-
tary Material, Fig. S3D and E).
Figure 3.ZNF37Amodulates IL13RA1expression. (A)Quantitative real-timeRT–PCRofZNF37A and IL13RA expression in undifferentiatedDM1 (VUB03_DM)
hES cell lines and in their differentiated derivatives NPC andMSC). (B) Quantitative real-time RT–PCR of IL13RA expression in primary cultures of myotubes iso-
lated fromDM1patients (resultswere normalizedwith the average of control samples).Data are presented as scatter dot plot (line atmean) andwere analyzedwith the
t-test, ∗P, 0.05. (C) Quantitative real-time RT–PCR of ZNF37A and IL13RA1 expression after siRNA-induced knock down in controls (H9) hES-derived MSCs.
(D) Chromatin immunoprecipitation of ZNF37A on IL13RA1 promoter. Different primers have been designed to cover a large region surrounding the transcription
start site (TSS) and their localization is schematically indicated. Data are expressed as percent precipitation relative to input (mean+SEM, n ¼ 4).
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IL13RA1 is part of the common receptor for IL4 and IL13, two
cytokines that participate to the recruitment of myoblasts and
promote myogenic fusion (16,17). Function of ZNF37A was,
therefore, evaluated on muscle cell differentiation. Control
human primary myoblasts transfected either with one of two dif-
ferent siRNA against ZNF37A (Supplementary Material,
Fig. S4A and B) or with control siRNA were differentiated into
myotubes. Down expression of ZNF37A did not affect the
generation of myotubes, as determined by the detection of
myosin heavy chain (MF20 positive cells). In contrast, a defect
in the number of nuclei per MF20 positive cells was observed,
similar to that observed in human primary myoblasts derived
from DM1 patients (Fig. 4; Supplementary Material, Fig. S4C).
These results suggested that the down expression of ZNF37A
might not affect the differentiation process, but instead plays a
role in the myoblast fusion at a specific stage of myogenesis
Figure 4.Down expression of ZNF37A affects myogenic differentiation in vitro. Detection of myogenic markers by immunostaining 6 days after specific ZNF37A
siRNA transient transfection in control myoblasts. Desmin detects muscle cells (green); MF20 detects differentiated myoblasts (red) and Dapi (blue) labels nuclei.
Scale bar ¼ 50 mm.Quantification of themyogenic impairment ismeasured by the number of nuclei perMF20positive cells. A total of1000MF20was counted for
each condition. Data are presented as mean+SEM (n ¼ 3) and were analyzed with a ‘Bonferroni’s multiple comparison test’ (one-way ANOVA), ns: no statistical
difference, ∗P , 0.05, ∗∗P , 0.001.
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after the initial formation of a myotube. No statistical difference
was observed between DM1 myotubes and siZNF37A-treated
cells, suggesting that the down expression of ZNF37A led to a
similar phenotype to that observed in DM1 cells. This action
window of ZNF37A on myogenesis could be correlated with the
one of the cytokines IL13 and IL4, which reinforced the hypoth-
esis of amechanistic action of ZNF37Avia IL13RA1.Tovalidate
this point, the effect of IL4/IL13 treatment on myogenesis was
compared between DM1 cell cultures and wild-type cells
treated to knock down the expression of ZNF37A. In the controls,
IL4/IL13 treatment increased theability ofwild-typemyoblasts to
mature intomultinucleatedmyotubes. Insharpcontrast,nosimilar
effect of the treatment was observed in either DM1 myoblasts or
wild-type myotubes after knocking down the expression of
ZNF37A using specific siRNAs (Fig. 5) which thus establishes
the contribution of ZNF37A to the myogenic effect of IL4/IL13.
DISCUSSION
The main finding of this study is the demonstration that, in cells
carrying the DM1 mutation, the observed decreased expression
of the transcription factor ZNF37A bears functional conse-
quences for myogenesis. These results from a defect in IL4/
IL13 signaling that may involve alteration of expression of the
IL13RA1 receptor subunit. At themolecular level, theDM1mu-
tation most likely affects ZNF37A expression via a mechanism
that involves abnormal control of its mRNA stability by the
RNA-binding Protein CUGBP1.
The currently accepted pathological model of DM1 holds that
manifestations result from alteration of two main proteins
involved in pre-mRNA splicing, namely MBNL1, which is
sequestered in the nucleus due to its association with the repeat-
containing mRNA (18), and CUGBP1, which is overexpressed
and hyperphosphorylated in the nucleus of DM1 cells (19).
Recent studies have shown that not all DM1 pathological
mechanisms can be explained by altered alternative RNA spli-
cing. By characterizing affected genes in a DM1 transgenic
mousemodel expressing 250CUG repeats in 3′UTRof the skel-
etal actin mRNA, Osborne et al. have shown that RNA contain-
ing (CUG) expansions interfere at both transcriptional and
posttranscriptional levels (20). Similarly, the misexpression of
CUGBP1 contributes to the alteration in muscle development
in DM1 by affecting the translation efficiency of p21 via
binding to a GC-rich sequence located within the 5′ region of
p21 mRNA (21,22). CUGBP1 also acts as an mRNA stabilizing
factor associated with short-lived mRNAs (23) and contributes
to muscle wasting in DM1 by affecting the decay of TNF
mRNA in DM1 muscle cells (13). Collectively, these observa-
tions and our results support the conclusion that the function of
CUGBP1 on the turnover of mRNA has a more extensive
impact on DM1 pathogenesis than previously thought.
The involvement of a zinc-finger transcription factor in DM1
requires a comparison with DM2, a myotonic dystrophy disorder
characterizedbyCCUGmRNAexpansions (24) inZNF9, another
memberof zinc-finger transcription family.Theclinical analogies
between DM1 and DM2 have led to the suggestion of a common
trans-acting mechanism with depletion of similar transcription
factors (25). The observation that haploinsufficiency for Znf9 is
associated with multiorgan abnormalities resembling myotonic
dystrophy reinforces this notion (26,27). It is therefore tempting
to postulate that a common requirement for transcription factors
in tissues expressing the mutant DMPKmay be partially respon-
sible for someof themultisystemic symptomatologyofDM1(e.g.
myotonia, myopathy, insulin resistance, cognitive impairment).
To address this issue, it would be interesting to undertake a sys-
tematic search for target genes impacted by the loss of ZNF37A
expression in DM1.
The DM1 mutation interferes with myogenesis, but the exact
mechanism of this phenomenon has not yet been clarified (3,28).
IL13 and IL4 can be considered as interesting candidates
because of their role in myoblast fusion during muscle develop-
ment and regeneration (16,17,29). It was, therefore, particularly
interesting to observe that ZNF37A, which interferes with myo-
genesiswhen defective, was found tomodulate the expression of
IL13RA1. This gene encodes a receptor subunit that combines
with IL4RA to form the heterodimeric receptor for the IL4 and
IL13 cytokines (30). IL13RA1 expression also increases soon
after muscle injury, suggesting that this receptor plays a role in
muscle regeneration (31). Increased expression of IL13RA1 in
DM1 cells as a consequence of a loss of expression of ZNF37A
may, therefore, bear some significance formyogenesis and/or re-
generation (32–35). Consistent with this, DM1 differentiated
myoblasts did not respond to IL13/IL4 treatment in an in vitro
model of myogenic fusion as control cells did.
However, it has been shown that IL-4 and IL-13 could share
the redundant ability to recruit mononucleated cells for fusion
but not toward the same cell populations: IL-4 being responsible
for the ‘normal’ myoblast fusion into nascent myotubes during
myogenic differentiation, and IL-13 for additional recruitment
of reserve cells during skeletal muscle hypertrophy that may
prevent the loss of muscle mass (16,17,29). Therefore, it will
be interesting to determine the exact function of IL4 and IL13
in the DM1 phenotype observed.
Most previous analyses of DM1 pathological mechanisms
attempted toassociate clinical symptomsandalterationof thepro-
cessing of specific candidate proteins. These hypothesis-driven
studies unavoidably ignored genes that could not be directly
linked to identified symptoms. We have begun to provide a com-
plementary list of genes that appear to be specificallymodified by
the presence of DM1 mutation by combining the use of
DM1-mutanthEScells-derivedprogeniesandglobalgeneexpres-
sion profiling. Although validation of the exact mechanisms by
which DM1 affects these genes has yet to be provided and the
effect of their abnormal expression on cell metabolism still has
to be defined, these genes are candidates for new pathological
pathways associated with DM1. We previously demonstrated
that this approach could be used to identify new physiopathologi-
calmechanisms implicated in the neuritogenesis and synaptogen-
esisofmotoneurons (5).Thepresent studyconfirms theusefulness
of such a resource-driven approach based on gene-carrying pluri-
potent stem cell lines. This study also highlights the potential
offered by the use of disease-specific human pluripotent stem
cells to decipher physiopathological mechanisms in a large spec-
trum of cell types, and therefore points out the added value of this
approach for multisystemic diseases.
5194 Human Molecular Genetics, 2013, Vol. 22, No. 25
MATERIALS ANDMETHODS
Cell culture
Mutants hES cell line (VUB03_DM, XX, passages p70–p90;
and VUB24_DM; XX, passages p30–40, derived in AZ-VUB)
and wild-type human ES cells (H9, XX, passages 40–60;
WiCell Research Institute; VUB01, XY, passages p80–90)
were maintained as previously described (36).
Control and DM1 myoblasts were cultured in D-MEM/F-12
medium (Invitrogen) supplemented with 20% SVF (Eurobio)
Figure 5. Down expression of ZNF37A affects the myogenic response to IL13/IL4 treatment. Immunostaining of DM1, siZNF37A transfected or untransfected
control myoblasts treated with IL13/IL4 (50/50 ng/ml) on Day 6 of differentiation. Desmin detects muscle cells (green); MF20 detects differentiated myoblasts
(red) and Dapi (blue) labels nuclei. White arrows indicate examples of polynucleated MF20 positive cells. Scale bar ¼ 50 mm. Quantification of the myogenic im-
pairmentwasmeasured by the number of nuclei perMF20 positive cells. A total of1000MF20was counted for each condition. Data are presented asmean+SEM
(n ¼ 3) and were analyzed with the ‘Bonferroni’s multiple comparison test’ (one-way ANOVA), ∗P , 0.05. NT: non-transfected.
Human Molecular Genetics, 2013, Vol. 22, No. 25 5195
and 0.1% of penicillin–streptomycin (Gibco). For differenti-
ation, cells were transferred to 2% SVF D-MEM/F-12 medium
for 6 days.
Neural and mesodermal differentiation were achieved using
established methods (5,10,37). Briefly, mesodermal stem cells
were obtained after plating hES cells onto gelatin-coated
plates with medium containing 20% of fetal bovine serum for
21 days. The purity of the mesenchymal cultures was validated
by FACS analysis for different markers such as CD73 (5,10).
hES cell lines were differentiated into neural precursor cells by
using a co-culture with MS5 stromal cells. After 2–3 weeks of
culture, neural precursor cells appear as neural rosette structures.
Neural precursor cells were FACS-sorted on the basis of NCAM
expression.
Control andDM1myoblasts with.2000 repeats (kindly pro-
vided by Dr. D. Furling) were isolated from quadriceps muscles
biopsies obtained from the Myobank in accordance with the
French legislation on ethical rules. The fetal brain RNA
(kindly provided byDr.G.Gourdon, InsermU781)was obtained
from fetuses aged from 12 to 25 amenorrhea weeks. DM1
samples were affected to different degrees (97–1500 CTG
repeats). The adult brain RNA samples (kindly provided by
Dr. M. Gomez-Pereira, Inserm U781) were obtained from cor-
tical biopsies of adult forms of DM1 and contained different
sizes of CTG expansion ranging from 200 to 1000.
Real-time reverse transcriptase polymerase chain reaction
and Agilent DNA chips analysis
Total RNA from cells was isolated using the ‘RNeasy Mini
Protocol’ (Qiagen). cDNA was synthesized by using Super-
Script III (Invitrogen). Quantitative real-time reverse transcript-
ase–polymerase chain reaction (RT–PCR) was optimized to
determine the linear amplification range by using a Chromo4
Real-Time System (Bio-Rad) with Syber Green PCR Master
Mix (Applied Biosystems). For Agilent Chips analysis, PCR
products were quantified using the DNA 1000 Kit for the
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto,
France) according to the manufacturer’s protocol. Primers are
listed in Supplementary Material, Table S1.
Actinomycin treatment
hES-derived MSCs control (H9) and DM1 (VUB03_DM) were
plated at 5 × 104 cells per well (70–80% confluency in 24-well
plate) and were treated with 5 mg/ml of Actinomycin (Sigma)
during 30, 90 and 180 min. Total RNA from cells was isolated
as described above and quantitative real-time RT–PCR was
performed.
Luciferase assays
5′UTR_ZNF37A-luc plasmid was obtained by PCR using spe-
cific primers amplifying DNA intron 1 to intron 3. The PCR
productwas purified and cloned in pGL4.82 (Promega)modified
with CMV promoter. HEK293 cells were plated at 2.5 ×
104 cells/cm2 in 96-well plate in Alpha MEM medium supple-
mented with 10% SVF (Hyclone) and 1% Glutamax, 1% non-
essential amino acids and 1% penicillin–streptomycin
(Gibco). Twenty-four hours after plating, the cells were
co-transfected with 100 ng of the 5′UTR_ZNF37A-luc, 100 ng
of Delta A or 100 ng of Delta B, 250 ng of the pGFP (Lonza)
and 250 ng of pCTG (960 interrupted repeats) or 100 ng of
pCUGBP1 or 100 ng of pMBNL1 plasmids in OptiMEM
mediumusingLipofectamineTM LTXPlusReagent (Invitrogen).
Forty-eight hours after transfection, the luciferase substrate was
applied using EndurenTM Live Cell Substrate (Promega). Lumi-
nescence reading was performed using Analyst GT (Molecular
Devices). For cell normalization, CellTiterGlow Luminescent
Cell Viability Assay (Promega) was used.
Transient siRNA knockdown
The sequences targeted by chemically synthesized siRNAs in
transient knockdown experiments were as follows:
Hs_ZNF37A_7 HP siRNA (Qiagen), Hs_ZNF37A_9 HP
siRNA (Qiagen) and Silencerw Negative Control siRNA
(Ambion, Applied Biosystems). MSCs were plated at 5 × 104
cells per well (70–80% confluency in 24-well plate) and were
transfected the following day with 10–40 nmol siRNA in
OptiMEM medium by using LipoRNAiMax (Invitrogen).
Myoblasts were plated at 8 × 104 cells per well in 12-well
plate. The following day, they were transfected with 10 pmol
siRNA in OptiMEM medium by using Lipofectamine 2000
(Invitrogen) in differentiated medium. Forty-eight hours after
transfection, RNA was isolated and quantitative real-time
RT–PCRwas performed as described above to check the specif-
ic ZNF37A down expression.
Immunocytochemistry
Cultured cells were fixed in 4% paraformaldehyde in PBS and
were incubated with the monoclonal antibody against ZNF37A
(R&DSystem, 1/500) at 48C for 12 h.Appropriate FITC-labeled
secondary antibodies (Jackson ImmunoResearch) were used.
For myogenic characterization, the cells were fixed in 4% paraf-
ormaldehyde in PBS and were incubated with the monoclonal
antibody MF20 (DSHB, 1/200) and Desmin (1/25 R&D
System) at RT for 2 h. Then the cellswere incubatedwithMono-
clonalCy3andCy2andDapi atRTfor2 h. Imageswere captured
using a Zeiss fluorescent microscope.
Chromatin immunoprecipitation
Chromatin immunoprecipitation analyses were carried out as
described (38,39). Briefly, genomic DNA and proteins were
cross-linked by formaldehyde (1% final) and quenched with
glycine 1 M. Cells were sonicated eight times to generate 100–
1000 bp DNA fragments. Before addition of antibody, 100 ml
of lysate was saved as the input sample. Either anti-acetyl H3,
CT, pan A3S (Millipore, 5 mg), monoclonal anti-ZNF37A
(R&D System, 5 mg), monoclonal anti-Isl2 or MAP2 (DSBH
Bank, 5 mg) was incubated with lysates overnight at 48C.
Immune complexes were purified using Dynead beads (Invitro-
gen) and eluted at 1008C for 10 min. DNA was extracted using
purification columns (Nalgene) and quantitative PCR was
carried out and analyzed as described in (40) using the primers
described in Supplementary Material, Table S1.
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In vitro transcription and gel shift assay
RNAs for gel shift experiments were transcribed using a cap
analog and SP6 polymerase in the presence of a-32P-[UTP].
RNAmobility shift assays were performed with increasing con-
centrations of recombinant CUGBP1 as described previously
(41). Recombinant proteins were diluted in buffer D containing
0.5 mg/ml bovine serum albumin. The reaction was incubated
for 15 min at 308C, and the protein complexes were resolved
by electrophoresis on a 6% non-denaturing polyacrylamide gel
(39/1), 0.5× TBE. RNA bands were quantified using a Phos-
phorImager (Molecular Dynamics)
Co-immunoprecipitation and western blot analysis
Co-immunoprecipitation and western blot analyses were per-
formed as previously described (42). Briefly, proteins were
extracted with RIPA buffer (Invitrogen) and were quantified
using a BCA protein assay kit (Pierce). For co-immunoprecipi-
tation, 100 mg of proteins were incubated overnight at 48C with
10 mg of antibodies against either ZNF37A (Abnova) or Kap1
(Abnova). Precipitation were performed with Dynabeadsw
Protein A (LifeTechw) according to manufacturer’s protocol.
For western blot, 15 mg of proteins were loaded on NuPAGE
4–12%Bis-TrisGels (Invitrogen) and transferred onto a nitrocel-
lulose membrane (Invitrogen). Primary antibodies for ZNF37A
(1/500, Abnova), H3 PAN (1/1000, Millipore), b-Actin (1/100
000, Sigma), MBNL1 (1/7000, kindly provided by Dr. Furling)
and CUGBP1 (1/1000, Santa Cruz Biotechnology) have been
used. Western blot proteins were determined by using Novex-
wECLKit (LifeTech). For ZNF37A blots, nuclear and cytoplasm
proteins were extracted using NE-PER Extraction Kit (Pierce).
IL13/IL4 treatment
Myoblasts were plated at 8 × 104 cells per well in 12-well plate.
The following day, they were treated with 50 ng/ml of IL13 and
IL4 (R&DSystem) in differentiation medium. Themediumwas
changed after 4 days, and the cells were fixed on day 6.
Statistical analysis
The datawere processed using Prism5.0c. Values are reported as
means+SEM. Comparisons between two groups were made
with Student’s t-test (ANOVA). For comparisons of more than
two groups, ‘Bonferroni’s multiple comparison test’ (one-way
ANOVA) was performed.
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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